Next Article in Journal
Yeast Diversity in Wine Grapes from Japanese Vineyards and Enological Traits of Indigenous Saccharomyces cerevisiae Strains
Previous Article in Journal
Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements
Previous Article in Special Issue
The Effects of Aspirin Intervention on Inflammation-Associated Lingual Bacteria: A Pilot Study from a Randomized Clinical Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 12
Issue 9
10.3390/microorganisms12091768
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Ambiguous Correlation of Blautia with Obesity: A Systematic Review

by
Warren Chanda
1,2,
He Jiang
1,* and
Shuang-Jiang Liu
1,3,4,*
1
State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China
2
Pathology and Microbiology Department, School of Medicine and Health Sciences, Mulungushi University, Livingstone P.O. Box 60009, Zambia
3
State Key Laboratory of Microbial Resources, and Environmental Microbiology Research Center (EMRC), Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
4
University of Chinese Academy of Sciences, Beijing 100049, China
*
Authors to whom correspondence should be addressed.
Microorganisms 2024, 12(9), 1768; https://doi.org/10.3390/microorganisms12091768
Submission received: 30 July 2024 / Revised: 13 August 2024 / Accepted: 17 August 2024 / Published: 26 August 2024
(This article belongs to the Special Issue Gut Microbiome in Homeostasis and Disease, 2nd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Obesity is a complex and multifactorial disease with global epidemic proportions, posing significant health and economic challenges. Whilst diet and lifestyle are well-established contributors to the pathogenesis, the gut microbiota’s role in obesity development is increasingly recognized. Blautia, as one of the major intestinal bacteria of the Firmicutes phylum, is reported with both potential probiotic properties and causal factors for obesity in different studies, making its role controversial. To summarize the current understanding of the Blautia–obesity correlation and to evaluate the evidence from animal and clinical studies, we used “Blautia” AND “obesity” as keywords searching through PubMed and SpringerLink databases for research articles. After removing duplicates and inadequate articles using the exclusion criteria, we observed different results between studies supporting and opposing the beneficial role of Blautia in obesity at the genus level. Additionally, several studies showed probiotic effectiveness at the species level for Blautia coccoides, B. wexlerae, B. hansenii, B. producta, and B. luti. Therefore, the current evidence does not demonstrate Blautia’s direct involvement as a pathogenic microbe in obesity development or progression, which informs future research and therapeutic strategies targeting the gut Blautia in obesity management.

1. Introduction

Obesity is a complex and multifactorial disease characterized with a body mass index (BMI) of over 30 kg/m2. It is influenced by a combination of factors, including intestinal microbiota, genetic background, diet and lifestyle, and environment. Being a serious threat to public health, obesity increases the risk of various health conditions (Figure 1A), such as obstructive sleep apnea, which is accompanied by hypertension, insulin resistance, systemic inflammation, visceral fat deposition, and dyslipidemia [1,2]; stroke; hypercholesteremia; diabetes mellitus [3,4]; non-alcoholic fatty liver disease [5]; osteoarthritis [6]; asthma and chronic pulmonary disease [7]; infertility in both men and women [8,9]; depression [10]; and various types of cancers, such as breast, colon, liver, ovarian cancers, etc. [11]. As reported in 2021, over 40% of adults globally are overweight or obese, with projections indicating that, by 2030, 20% of the adult population will be affected [12,13,14]. In China, the rates of overweight and obesity among adults (≥18 years old) have reached 34.3 and 16.4%, respectively [15].
The commonly practiced solutions to control obesity and body weight are bariatric surgery and lifestyle management. While lifestyle-based weight loss strategies that combine diet, exercise, and behavioral changes (e.g., reducing sedentary behavior) can initially be successful, they often lead to weight regain due to metabolic adaptations [16]. Thus, there is a growing interest in pharmacological solutions, particularly those targeting the gut microbiota—the diverse community of microorganisms residing in the gastrointestinal tract. These microorganisms, which play crucial roles in nutrient metabolism and immune function, influencing the overall health and disease [17,18,19]. Research has shown that obesity is associated with reduced gut microbiota diversity and has identified key taxa, including Blautia, that exhibit significant alterations in obese individuals [20,21]. These alterations can be affected by underlying conditions such as diabetes and metabolic syndrome [21,22]. Additionally, the gut microbiota impacts energy metabolism and the production of short-chain fatty acids (SCFAs)—fatty acids with fewer than six carbon atoms, primarily produced by the fermentation of dietary fibers by gut bacteria. SCFAs, such as acetate, propionate, and butyrate, which help regulate energy balance and inflammation, contribute significantly to host metabolism and health [20].
Blautia, a genus within the Lachnospiraceae family, comprises 3–11% of the human intestinal microbiota [23,24,25]. Although only a few child taxa (23 out of 53 classified species) are validly published (Supplementary Table S1), Blautia is commonly detected in human fecal samples from both healthy and diseased individuals (Figure 1B). Some studies suggest that Blautia may positively influence the lipid metabolism and reduce visceral fat accumulation [25,26,27]. However, its role in obesity remains ambiguous, with conflicting evidence regarding its impact on health [27,28,29,30,31,32,33]. This highlights the need for a comprehensive evaluation of Blautia’s complex interaction with the host to understand its specific role in metabolic disorders such as obesity.
This systematic review aims to summarize the recent findings on Blautia’s role in obesity. We analyzed 170 research articles to explore the abundance of Blautia in the gut microbiome of obese individuals concerning treatment and lifestyle interventions. Additionally, we explored how Blautia populations respond to any treatments and lifestyle changes in obese individuals, examining associations between changes in Blautia abundance and the efficacy of employed interventions in managing obesity. Lastly, we discuss the potential of Blautia as a probiotic or source of beneficial metabolites for promoting health.
Microorganisms 12 01768 g001
Figure 1. The associations of obesity with some concomitant diseases (A), and the prevalence of Blautia in phenotypes (B). Panel B was generated from data compiled by the GMRepo (Gut Microbiota Repository) database. The prevalence of Blautia (red) in the total number of samples processed per phenotype (blue) is shown [34,35] (https://gmrepo.humangut.info/taxon/572511, accessed on 15 July 2024).
Figure 1. The associations of obesity with some concomitant diseases (A), and the prevalence of Blautia in phenotypes (B). Panel B was generated from data compiled by the GMRepo (Gut Microbiota Repository) database. The prevalence of Blautia (red) in the total number of samples processed per phenotype (blue) is shown [34,35] (https://gmrepo.humangut.info/taxon/572511, accessed on 15 July 2024).
Microorganisms 12 01768 g001

2. Methods

2.1. Literature Search Strategy

We utilized PubMed and SpringerLink search engines as our primary tools, employing a key Boolean phrase “Blautia” AND “Obesity” to identify relevant articles for our systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [36]. We considered animal models and clinical research papers published from January 2013 to March 2024, while review articles were excluded.

2.2. Study Selection

Two independent reviewers guided by the inclusion and exclusion criteria conducted an initial assessment of the titles and abstracts of all the retrieved articles. Any conflicts that emerged over research study selections were resolved by discussion with the authors. The PICOS (Population, Intervention, Comparison, Outcome, Study design) framework was used to define the eligibility criteria.
PICOS criteria:
  • Population: Animal models and human subjects
  • Intervention: Any treatment or lifestyle interventions affecting gut microbiota
  • Comparison: Factors inducing gut microbiota changes, including Firmicutes/Bacteroidetes (FB) ratio, molecular methods used, treatment period, and subjects’ country
  • Outcome: Changes in Blautia abundance and obesity status
  • Study design: Original research articles

2.3. Data Extraction

With the aim to summarize the understanding of the associations and mechanism between Blautia and obesity, we particularly considered research articles that reported variables covering the effect of medical treatment or lifestyle on the status and dynamics of Blautia, factors that induced gut microbiota changes (including FB ratio, molecular method used, treatment period, and country of subjects), and variables related to the associations and mechanisms between Blautia and obesity (or overweight) were independently extracted by the authors using a standardized data extraction form in Microsoft Excel 2021.

2.4. Bias Evaluation

All studies meeting the inclusion criteria were considered for data extraction, irrespective of their quality. The potential risk of bias was assessed by evaluating three domains (selection bias, performance bias, and detection bias), following O’Connor and Sargeanti’s extraction [37] from the Cochrane Handbook of Systematic Reviews of Interventions and adapted for animal studies in preclinical medicine [38]. Two independent reviewers performed the bias evaluation, and any disagreements were resolved through discussion or by consulting a third reviewer.

2.5. Data Synthesis

Descriptive statistics and association tests, including Spearman’s correlation and/or chi-square tests, were performed using IBM SPSS Statistics version 20 software.

3. Results

3.1. Studies Overview

Following a comprehensive search of the SpringerLink and PubMed databases, 1378 research articles published between January of 2013 and March of 2024 were found and retrieved. Of these, 170 articles that satisfied the inclusion criteria were chosen for in-depth analysis after a thorough screening process (Figure 2A). Of the above 170 articles analyzed, varying proportions of the selected variables of interest were observed (Figure 2B). Among these variables, the publication year highlighted an increasing pattern of Blautia and obesity-related studies until 2022, then a drop in 2023, with mice, children, and adults being the commonest study subjects. Gut microbiota alterations in relation to obesity were mostly induced with prebiotic supplementation. To summarize the roles that Blautia played in obesity-related gut microbiota studies, it could be descripted as either “good” or “bad”, depending on whether the Blautia abundance was negatively or positively associated with obesity and other side symptoms, respectively. Briefly, Blautia was described as “good” in >60% of the studies evaluated (Figure 2B). This was mostly attributed to the increased level of Blautia detection in interventional studies, Blautia’s ability to produce metabolites (such as SCFAs) that alleviated obesity and related indices, and the observed suppression of obesity in some subjects compared to the control group. Additionally, the use of Blautia as probiotic agents had significant ameliorating effects, suggesting its potential role in promoting health (Supplementary Dataset S1). Interestingly, the Firmicutes-to-Bacteroidetes (FB) ratio was lowered in the majority of obese cases (Figure 2B), highlighting the importance of understanding microbial interactions and their implications for host health. We observed that the FB ratio may decrease in circumstances where Blautia increases, especially with prebiotic supplementation [39,40,41], diet alteration [42], or surgery [43,44,45]. Additionally, an increasing FB ratio was associated with either an increase or decrease in obese subjects regardless of whether the Blautia status was “good” or “bad” (Figure 2B and Supplementary Dataset S1), indicating that the FB ratio varies and cannot be used as a reliable predictor of obesity, since alterations at the phylum level do not always translate to all members at the family or genus level. 16S rRNA sequencing was a predominant molecular method used with a focus on the V3–V4 regions. However, none of the studies sequenced the full length (~1500 bp) of the 16S rRNA gene, except for the studies by Sun et al. [46] and Gómez-Pérez et al. [42], which sequenced the longest regions (V3–V9 and V2–V9, respectively) (Figure 2B and Supplementary Dataset S1). Finally, a suitable treatment period is crucial when examining the impact of treatment regimens with fewer adverse effects [47,48]. Most studies assessed their therapies for 12 weeks, followed by 8 and 4 weeks (Figure 2B). Additionally, the majority of the pooled studies were conducted in China, followed by Spain, Japan, and the United States. Other geographical regions had fewer studies (<2%), but when combined, they produced a well-represented geographical distribution (Figure 2B).
Since most studies induced changes in the gut microbiota through medical treatments (such as bariatric surgery and fecal microbiota transplantation) and lifestyle management (including diet, exercise, prebiotics, and probiotics), and to explore the dynamics of Blautia populations in obese individuals concerning these interventions, the results will be organized according to these criteria.

3.2. Status and Dynamics of Blautia Population during Medical Treatment and Lifestyle Managements in Obese Individuals

3.2.1. Surgery

Bariatric surgery is often regarded as the primary therapy for obese and overweight individuals. The most common procedures include sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) [49]. RYGB is excellent at reducing weight, but bypassing the large section of the stomach and the upper part of the small intestine reduces the absorption of essential vitamins and trace elements, causing nutritional deficiencies and, consequently, impacting the gut microbiota [50]. On the other hand, SG is a restrictive procedure that reduces the stomach size to about 15–25%, which has less impact on the nutritional deficiency and gut microbiota [50]. The data show that SG but not RYGB may be associated with an improvement in obesity due to an increase in the abundance of Blautia post-surgery, which significantly reduces host weight gain, inflammatory factors, and visceral fat accumulation (Supplementary Dataset S1) [43,44,45,49,51,52]. Additionally, an increase in ursodeoxycholate, which may improve liver health and prevent gallstone disease, was observed [51,53]. Therefore, the increased abundance of Blautia in the gut microbiota after bariatric surgery may also serve as a potential indicator of successful weight loss and improved metabolic health [45].

3.2.2. Diet

The ketogenic diet (approximately 10% carbohydrates, 70% fats, and 20% protein) and the Mediterranean diet are thought to be beneficial for weight management in terms of changes in the gut microbiota (as discussed in Ref. [16]). Evaluating the effect of these diets on Blautia may help predict its involvement in health and obesity. Among the clinical studies analyzed (Table 1), a decreased calorie intake enhanced the amount of Blautia, which had a positive influence on health. A combination of diet and exercise [54], medium-protein and low-fat diets [55], the Mediterranean diet and exercise [42], improved ketogenic diet and exercise [56], and hypocaloric hyperproteic diet [57] enhanced the Blautia levels, leading to the amelioration of obesity and its related indices. However, a study that paired an enhanced ketogenic diet with exercise discovered that B. obeum had a favorable correlation with VFA, whereas B. producta, B. hansenii, B. wexlerae, and Blautia sp. CAG257 showed negative associations (Table 1, [56]). This observation may be due to a species- and/or strain-specific response of Blautia that may not be generalized to the entire genus. Together, these studies underscore the importance of diet composition for boosting the potential probiotic usage of strain-dependent Blautia levels to alleviate obesity.

3.2.3. Exercise

Regular exercise is known to lower the incidence of metabolic diseases [61]. Despite exercise being recommended for improving health in overweight or obese individuals, its specific effects on the gut microbiota composition, particularly with Blautia, remain unclear. Quiroga et al. [62] emphasized that exercise enhances the abundance of Blautia, which correlated with reduced adiposity, improved lipid profiles, and decreased inflammation in obese children. Additionally, short-term and high-intensity interval training has been shown to increase the abundance of bacterial species such as Coprococcus_3, Blautia, and Dorea, correlating with markers of insulin sensitivity in overweight individuals but not affecting the gut bacterial diversity in lean or overweight men [61]. Whether the observed increase in Blautia abundance and exercise exerted a synergistic effect on the disease outcomes requires further investigation.
Furthermore, aerobic exercise has been found to increase circulating levels of endocannabinoid agonists, including anandamide and 2-arachidonoylglycerol, which play crucial roles in appetite regulation, metabolism, stress modulation, and inflammation [63,64], thereby reducing the occurrence of obesity [65]. Palmitoylethanolamide (PEA), similar to cannabidiol in its pharmacodynamic properties, inhibits the degradation of these endocannabinoid agonists [66,67] and has been reported to associate with increased Blautia abundance and alleviation of anhedonia/amotivation [68]. Given that both Blautia and cannabidiol/PEA help preserve the gut barrier integrity [69,70] and reduce colonic permeability [67], it is plausible that Blautia is involved in regulating the endocannabinoid levels in conjunction with exercise.

3.2.4. Probiotics

Probiotics are defined as living microorganisms that, when administered in adequate amounts, confer health benefits to the host, often by modulating the gut microbiota. There is a paucity of studies on the interaction of Blautia with other potential probiotic strains in obesity management. Zhao et al. [71] found a reduced level of Lactobacillus, Allobaculum, and Blautia in the high cholesterol diet group compared to the normal diet group in C57BL/6 male mice. However, treatment with the lactic acid bacterium, Lactiplantibacillus plantarum WLPL21, restored these taxa. The study also discovered a positive correlation of serum and liver cholesterol with Desulfovibrio and Lachnoclostridium, while a negative correlation was noted with Blautia, Allobaculum, and Lactobacillus. Similarly, Jing et al. [72] found that the administration of Bacillus sp. DU-106 in C57BL/6J mice restored the abundance of Blautia, Ileibacterium, Faecalibaculum, Faecalibacterium, and unidentified_Lachnospiraceae, which were reduced by a high-fat diet. However, a 12-week intervention with Lactobacillus salivarius Ls-33 among obese adolescents detected no significant alteration of the Blautia coccoides–Eubacterium rectale group in patients before and after probiotic intake [73]. Although the detection method (RT-qPCR) was less sensitive due to its multispecies amplification, the results indicate that Blautia may have a specific role in disease management (Ref. [73], Supplementary Dataset S1). In support of this, the administration of B. hansenii improved obesity in C57BL/6J mice by increasing its abundance [74]. These findings imply that, while Blautia plays a role in cholesterol metabolism, its effects may be enhanced by interspecies interactions with the gut microbial community.

3.2.5. Prebiotics

Prebiotics are a category of non-digestible food components that selectively stimulate the growth and/or activity of beneficial gut bacteria. Numerous in vivo and clinical studies have shown that prebiotics can promote host health by enhancing the growth of beneficial gut bacteria, which subsequently regulates the balance of the gut microbial flora, heightens the gut resistance to diseases, and influences the host immunity [75,76]. The use of prebiotics such as arabinoxylan, berberine, celery juice, d-arabitol, inulin, resveratrol polyphenol, silybin, yacon, etc. (Figure 3A, green box) elevated the levels of Blautia, as well as some other SCFA-producing bacteria such as Bacteroides and Akkermansia, while inhibited lipopolysaccharide (LPS)-producing and proinflammatory bacteria, resulting in a significant increase of SCFAs, especially butyric acid, reduced serum LPS levels and inflammation, and regulating visceral fat and hepatic lipid metabolism (Supplementary Dataset S1) [41,77,78]. Conversely, the administration of prebiotics such as adzuki beans, mung bean seed coat, moringa oleifera polysaccharides, quinoa, vitamin D, etc. (Figure 3A, red box) improved weight management but decreased the abundance of Blautia (Supplementary Dataset S1). These findings suggest Blautia’s potential probiotic role in obesity, with prebiotics having varied impacts on its abundance, highlighting the importance of prebiotic selection when targeting Blautia for probiotic effects.

3.2.6. Fecal Microbial Transplant (FMT)

Fecal microbiota transplantation (FMT) is a medical procedure that involves transferring fecal microorganisms from a healthy donor into the gut of a recipient to treat specific diseases [80,81]. FMT is associated with mixed results in obesity management, with some promising effects, especially in improving insulin sensitivity, but with limited impact on weight loss [80,82]. Participants with BMI ≥ 35 kg/m2 administered autologous FMT or from a healthy lean donor had a notable increase in the abundance of Bacteroides and Blautia, coupled with reduced serum levels of branched-chain amino acids (isoleucine and leucine), decenoylcarnitine, and fecal phenylacetic acid [81]. Elevated serum levels of branched-chain amino acids and decenoylcarnitine are recognized markers of obesity and insulin resistance, attributed to the activation of the mammalian target of rapamycin complex 1 (mTORC1) [83,84,85]. Conversely, changes in the fecal phenylacetic acid levels may signify alterations in the gut microbial metabolism associated with obesity. A decrease in its concentration suggests a favorable shift towards a healthier gut microbiome composition and function [81,86]. While FMT had no effect on weight loss before bariatric surgery [80], the increased abundance of Blautia and decreased metabolites associated with obesity and insulin resistance in serum underscore the importance of identifying and using selected species like Blautia with probiotic potential.

3.3. Association between Blautia and Obesity

Blautia species have the potential to impact obesity through multiple pathways, such as modifying energy metabolism, reducing inflammation, and influencing the composition of the gut bacterial community [28,87,88]. Improvements in glucose metabolism, such as increased insulin sensitivity, which controls the blood glucose levels, are among the suggested mechanisms [29,74]. Furthermore, Blautia can affect the metabolism of fatty acids, lowering the accumulation of harmful lipid species in the liver and altering the composition of circulating bile acids, which are involved in fat absorption [28,29,41]. Moreover, Blautia species have the ability to regulate immunological responses and support the integrity of the intestinal barrier, which may positively impact metabolic health and reduce systemic inflammation [28,29,41].

3.3.1. Association of Blautia and Obesity in Children and Adolescents

Childhood obesity is a prognostic marker of adult obesity, and the prevention of obesity in children may help to address the epidemic [10]. The diversity of gut microbiota in children can be influenced by maternal health status (obese/overweight or lean), mode of delivery (vaginal vs. cesarean section), and feeding practices (exclusive breastfeeding or alternative methods, with formula-fed infants showing an increased risk of overweight compared to breastfed infants [89]). Consequently, offspring born to obese mothers are presumed to have an elevated risk of obesity, potentially linked to the transmission of obesogenic microbiota. However, despite children born to obese mothers exhibiting a lower carbohydrate content, reduced levels of Blautia and Eubacterium, and increased levels of Parabacteroides and Oscillibacter, no significant associations were found between the gut microbial community structure and environmental factors such as delivery mode, breastfeeding duration, or maternal and infant antibiotic exposure [90]. The reduced levels of Blautia may be impacted by other factors besides dietary composition, as there is a lack of association between protein, fat, carbohydrate, or fiber intake and Blautia abundance [25].
While Blautia species are associated with obesity in children, as noted by the “good” and “bad” status in studies involving children (Supplementary Dataset S1), the relationship is complex and may depend on factors such as age, inflammation, and diet. One study indicated the presence of Blautia in a meconium sample that disappeared within the first 5 months of the child’s life and reappeared in month 6 (Figure 3B, data extracted from the Supplementary Dataset of Ref. [79]). Some Blautia species (e.g., B. luti and B. wexlerae) are reported to have anti-inflammatory and anti-obesity effects, while others (e.g., B. producta) are negatively correlated with inflammatory markers like LPS binding protein (LBP), showing an opposite correlation with obesity [88].
Blautia’s role in ameliorating obesity would also be observable in adolescents. However, one study found varying levels of B. faecis and B. wexlerae in normal weight healthy donors compared to obese individuals, with B. producta associated with severe overall obesity in Italian adolescent subjects [91]. The significant level of Blautia abundance was observed in adolescent subjects who consumed Lactobacillus salivarius Ls-33 for 12 weeks compared to the placebo group [73]. This further complicates the association of Blautia with obesity, indicating the need for further investigation. Obesity, often resulting from a long-term imbalance between energy intake and expenditure, has been linked to energy-harvesting microbes like Blautia and Bacteroides [16]. While calorie restriction is a common practice in weight management, one study showed an increased relative abundance of Blautia in obese adolescents. However, this increase did not significantly impact the metabolic processes of the gut microbiome, such as energy harvesting or nutrient absorption, which might have been expected given Blautia’s role in carbohydrate metabolism [92].
These findings collectively suggest that Blautia depletion is associated with obesity and insulin resistance, and modulation after physical activity interventions restores it to resemble that of healthy children [93]. The beneficial effects of Blautia in children and adolescents may include, but are not limited to, contributions to carbohydrate metabolism and SCFA production, as well as anti-inflammatory, antioxidative, and anti-infective properties [26].

3.3.2. Blautia and Obesity among Adult Subjects

In studies involving adult human subjects, Blautia had been categorized as “good” in 66% (n = 35/53) of the reports (Supplementary Dataset S1), regardless of the FB ratio, genome sequencing, and treatment methods. Based on subjects’ geographical locations, all studies found Blautia had beneficial effects (>50%), except those from Australia, Poland, and Sweden with one study each and Finland with three studies (Figure 4 and Supplementary Dataset S1). An increasing pattern of studies describing Blautia as “good” was seen from the years 2018–2023, with all gut microbiota manipulation (inducer type) showing a >50% description of Blautia as “good”. Furthermore, a negative association of Blautia with obesity was seen in 97.2% (n = 35/36) of studies, while 100% (n = 17/17) reported a positive association (Figure 4 and Supplementary Dataset S1).
Significant differences in the gut microbial diversity between obese and non-obese individuals suggest a potential link between bacterial composition and obesity-related diseases. Kasai et al. [94] identified distinct bacterial species in Japanese obese subjects, including B. hydrogenotorophica, Coprococcus catus, Eubacterium ventriosum, Ruminococcus bromii, and R. obeum, whereas non-obese subjects showed Bacteroides faecichinchillae, Bac. thetaiotaomicron, B. wexlerae, Clostridium bolteae, and Flavonifractor plautii. This disparity underscores the varied associations of Blautia species with obesity in adults. Therefore, it is critical to identify specific species of Blautia with beneficial effects. For instance, B. hansenii and B. producta were negatively associated with VFA in a longitudinal study involving 767 Japanese subjects [27]. In another study, B. wexlerae demonstrated anti-obesity and anti-diabetic properties in Japanese adults, which was evidenced by its efficacy in reducing obesity and diabetes symptoms in mouse models [28]. The reported efficacy was associated with a unique metabolic pathway involving amino acid derivatives like S-adenosylmethionine and l-ornithine, as well as carbohydrate metabolism-producing SCFAs [28]. SCFAs activate G-protein-coupled receptors (GPCRs) in human adipocytes and colon cells enhancing insulin sensitivity through GPR 43 expression in adipose tissue [74,95,96,97]. Moreover, an increased abundance of Bacteroides and Blautia was associated with reduced serum levels of isoleucine, leucine, decenoylcarnitine, and fecal phenylacetic acid, which are recognized markers of obesity and insulin resistance [81,83,84,85].

4. Discussion

This comprehensive review aims to address the ongoing debate surrounding the role of Blautia in obesity, a topic that often elicits divergent opinions among scholars. The question of whether Blautia should be classified as a “friend” (beneficial) or “foe” (detrimental) in health and disease remains contentious, with many authors presenting biased perspectives shaped by their own research findings. In an effort to provide a more balanced assessment, we conducted a thorough examination of both in vivo and clinical data in accordance with PRISMA guidelines, specifically focusing on Blautia’s distinct association with obesity. Our objective was to determine whether Blautia should be viewed as a facilitator or a mitigator of disease risk, moving away from a simplistic “guilt by association” approach to a more nuanced evaluation of its impact.
Despite the scarcity of studies specifically evaluating Blautia’s role in obesity, examining its population dynamics in relation to gut microbiota manipulations can provide insights into whether Blautia should be considered a “friend” or “foe” in obesity management. Our comprehensive analysis of data from the GMRepo database [34,35] revealed significant variability in Blautia prevalence among the samples (see Figure 1B), indicating a potential association with host phenotypes. However, the presence of Blautia alone does not indicate causation, underscoring the need for experimental validation. The increased Blautia in obese adolescents without significant gut microbiota metabolic changes further highlights this complexity [92]. Certain bacteria can influence host conditions by secreting virulent or metabolic factors. Conversely, the absence of these factors may indicate a lack of participation in the observed phenotypes. Therefore, it is crucial not to draw simplistic conclusions, as the mere presence of bacteria does not necessarily imply a direct role in the condition. While the reviewed studies cannot establish a direct causal link between Blautia and the observed outcomes, they suggest a potential involvement in the development and prevention of obesity (Figure 5). Further investigations are needed to explore the causal relationship between Blautia and its effects, providing a deeper understanding of its role in these physiological mechanisms.
Blautia is a noteworthy genus of bacteria that has an impact on children’s growth and health that can last into adulthood. Extended periods of exclusive breastfeeding are linked to early life colonization of Blautia species, including B. luti and B. wexlerae, which may lay the foundation for a healthy gut microbiota [99]. Because its depletion is associated with childhood obesity and insulin resistance [29], it is plausible to link Blautia with metabolic health. Moreover, Blautia species have anti-inflammatory properties and are involved in the metabolism of carbohydrates, leading to the production of beneficial metabolites such as SCFAs [29,69,99]. The abundance of Blautia increases as children grow into adults [100], suggesting a fundamental role in mature gut function. This change may guard against obesity and prediabetic conditions while also assisting in the maintenance of gut immunological homeostasis [29,69]. Thus, with long-term effects that extend into adulthood, Blautia is important for children’s health and may be targets for microbiota-based therapies aimed at managing or preventing obesity and associated metabolic disorders. Their abundance and presence in the gut microbiome may also function as markers of metabolic health.
The relationship between obesity and metabolic syndrome has been extensively studied in regard to the Firmicutes–Bacteroidetes (FB) ratio; higher ratios have been related with obesity, while lower ratios have been linked to type 2 diabetes [101,102]. However, the FB ratio was not consistent with the Blautia species, which corroborated with previous findings [103]. Moreover, studies have shown that increasing the abundance of certain probiotic bacteria, including Blautia species, through probiotic and prebiotic supplementation may contribute to obesity management [28,74,104,105]. In addition to probiotic and prebiotic interventions, dietary modifications such as increased fiber intake have been shown to increase Blautia abundance in human participants [25,92].
Blautia species may exert their anti-obesity effects through various mechanisms, including altering energy metabolism [92], exerting anti-inflammatory effects [26,88], and changing the composition of the gut bacterial environment [87]. This means that methods to enhance Blautia abundance may be a viable strategy for assisting weight management initiatives, even though additional research is required to completely understand the potential of Blautia-targeted therapies.
Several limitations of this study must be acknowledged. Firstly, the scarcity of studies specifically focusing on Blautia’s role in obesity required us to include studies that reported alterations in Blautia among other gut microbiota taxa. Attributing specific functions to Blautia was challenging, because many studies also involved other bacterial species. Another limitation is that our review protocol was not registered with databases like PROSPERO, although we adhered to the PRISMA guidelines (Figure 2A). Additionally, our review only included articles from two databases, PubMed and SpringerLink, and was limited to English-language studies, which may have excluded relevant research. To mitigate study selection bias, at least two independent reviewers participated in the study screening and data extraction process. Despite these limitations, our findings contribute to a broader understanding of the link between Blautia and obesity and lay the foundation for future research. It is important to consider the implications of these results for practice, policy, and further investigation.
In conclusion, applying the concept of “guilt by association” to Blautia’s role in obesity may be premature, as the current evidence does not demonstrate Blautia’s direct involvement as a pathogenic microbe in the development or progression of obesity. Our study indicates that Blautia populations may change with different gut microbiota manipulations in obese individuals, potentially improving or exacerbating obesity. This variability may be due to species- or strain-specific effects, which should be considered when evaluating Blautia’s role in obesity. Some Blautia strains are capable of producing beneficial metabolites and inhibiting harmful products to the host (Figure 5). Notably, certain species within the Blautia genus, such as B. coccoides, B. wexlerae, B. hansenii, B. producta, and B. luti, have shown probiotic effectiveness (Figure 5). This calls for advanced sequencing methods, like shotgun sequencing or complete 16S rRNA gene sequencing, to provide better insights into Blautia species in diseased phenotypes and may help assigning an appropriate status to Blautia in obesity and related metabolic disorders. Additionally, more in vitro experiments are needed to explore Blautia’s functions for a better understanding of their roles in obesity. Lastly, Blautia’s presence can be influenced by interactions with other gut microbiota members, dietary components, or prebiotics, emphasizing the importance of careful dietary selection to appreciate its function in obesity.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/microorganisms12091768/s1: Dataset S1: Retrieved articles for systematic review, Supplemetary Table S1: List of Blautia species validly and correctively nominated under the International Code of Nomenclature of Prokaryotes (bacteriological code) [26,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126].

Author Contributions

Conceptualization, W.C. and S.-J.L.; methodology, validation, and analysis, W.C., H.J., and S.-J.L.; writing—original draft preparation, W.C.; writing—review and editing, H.J. and S.-J.L.; supervision, S.-J.L.; funding acquisition, S.-J.L. and H.J. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported financially by the National Key Research and Development Program of China, grant number 2021YFA090950203.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Materials, and any further inquiries can be directed to the corresponding author/s.

Acknowledgments

We would like to sincerely thank Matilda Mattu Moiwo and John Amos Mulemena for the initial assessment of the titles and abstracts of all the retrieved articles during the screening process.

Conflicts of Interest

The authors declare no conflicts of interest. The funder had no role in the design of the study, the writing of the manuscript, or in the decision to publish the results.

References

  1. Romero-Corral, A.; Caples, S.M.; Lopez-Jimenez, F.; Somers, V.K. Interactions between obesity and obstructive sleep apnea: Implications for treatment. Chest 2010, 137, 711–719. [Google Scholar] [CrossRef]
  2. Tuomilehto, H.; Seppä, J.; Uusitupa, M. Obesity and obstructive sleep apnea—Clinical significance of weight loss. Sleep. Med. Rev. 2013, 17, 321–329. [Google Scholar] [CrossRef] [PubMed]
  3. Wilson, P.W.; D’Agostino, R.B.; Sullivan, L.; Parise, H.; Kannel, W.B. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch. Intern. Med. 2002, 162, 1867–1872. [Google Scholar] [CrossRef] [PubMed]
  4. Sun, W.; Huang, Y.; Xian, Y.; Zhu, S.; Jia, Z.; Liu, R.; Li, F.; Wei, J.W.; Wang, J.-G.; Liu, M.; et al. Association of body mass index with mortality and functional outcome after acute ischemic stroke. Sci. Rep. 2017, 7, 2507. [Google Scholar] [CrossRef] [PubMed]
  5. Schwenger, K.J.P.; Bolzon, C.M.; Li, C.; Allard, J.P. Non-alcoholic fatty liver disease and obesity: The role of the gut bacteria. Eur. J. Nutr. 2019, 58, 1771–1784. [Google Scholar] [CrossRef]
  6. Kulkarni, K.; Karssiens, T.; Kumar, V.; Pandit, H. Obesity and osteoarthritis. Maturitas 2016, 89, 22–28. [Google Scholar] [CrossRef]
  7. Bianco, A.; Nigro, E.; Monaco, M.L.; Matera, M.G.; Scudiero, O.; Mazzarella, G.; Daniele, A. The burden of obesity in asthma and COPD: Role of adiponectin. Pulm. Pharmacol. Ther. 2017, 43, 20–25. [Google Scholar] [CrossRef]
  8. Calhoun, K.C. Obesity and Infertility. In Obesity During Pregnancy in Clinical Practice; Nicholson, W., Baptiste-Roberts, K., Eds.; Springer: London, UK, 2014; pp. 11–31. [Google Scholar]
  9. Mutsaerts Meike, A.Q.; van Oers Anne, M.; Groen, H.; Burggraaff Jan, M.; Kuchenbecker Walter, K.H.; Perquin Denise, A.M.; Koks Carolien, A.M.; van Golde, R.; Kaaijk Eugenie, M.; Schierbeek Jaap, M.; et al. Randomized Trial of a Lifestyle Program in Obese Infertile Women. N. Engl. J. Med. 2016, 374, 1942–1953. [Google Scholar] [CrossRef] [PubMed]
  10. Schneider, K.L.; Baldwin, A.S.; Mann, D.M.; Schmitz, N. Depression, obesity, eating behavior, and physical activity. J. Obes. 2012, 2012, 517358. [Google Scholar] [CrossRef]
  11. Park, J.; Morley, T.S.; Kim, M.; Clegg, D.J.; Scherer, P.E. Obesity and cancer—Mechanisms underlying tumour progression and recurrence. Nat. Rev. Endocrinol. 2014, 10, 455–465. [Google Scholar] [CrossRef]
  12. Spinelli, A.; Buoncristiano, M.; Nardone, P.; Starc, G.; Hejgaard, T.; Júlíusson, P.B.; Fismen, A.-S.; Weghuber, D.; Musić Milanović, S.; García-Solano, M.; et al. Thinness, overweight, and obesity in 6- to 9-year-old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative—COSI 2015–2017. Obes. Rev. 2021, 22, e13214. [Google Scholar] [CrossRef] [PubMed]
  13. Smith, K.B.; Smith, M.S. Obesity Statistics. Prim. Care: Clin. Off. Pract. 2016, 43, 121–135. [Google Scholar] [CrossRef] [PubMed]
  14. Zhao, Q.; Hou, D.; Fu, Y.; Xue, Y.; Guan, X.; Shen, Q. Adzuki Bean Alleviates Obesity and Insulin Resistance Induced by a High-Fat Diet and Modulates Gut Microbiota in Mice. Nutrients 2021, 13, 3240. [Google Scholar] [CrossRef]
  15. Pan, X.-F.; Wang, L.; Pan, A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021, 9, 373–392. [Google Scholar] [CrossRef]
  16. Van Hul, M.; Cani, P.D. The gut microbiota in obesity and weight management: Microbes as friends or foe? Nat. Rev. Endocrinol. 2023, 19, 258–271. [Google Scholar] [CrossRef] [PubMed]
  17. Jandhyala, S.M.; Talukdar, R.; Subramanyam, C.; Vuyyuru, H.; Sasikala, M.; Nageshwar Reddy, D. Role of the normal gut microbiota. World J. Gastroenterol. 2015, 21, 8787–8803. [Google Scholar] [CrossRef]
  18. Stefura, T.; Zapała, B.; Gosiewski, T.; Skomarovska, O.; Dudek, A.; Pędziwiatr, M.; Major, P. Differences in Compositions of Oral and Fecal Microbiota between Patients with Obesity and Controls. Medicina 2021, 57, 678. [Google Scholar] [CrossRef]
  19. Sonnenburg, J.L.; Bäckhed, F. Diet–microbiota interactions as moderators of human metabolism. Nature 2016, 535, 56–64. [Google Scholar] [CrossRef]
  20. Chanda, D.; De, D. Meta-analysis reveals obesity associated gut microbial alteration patterns and reproducible contributors of functional shift. Gut Microbes 2024, 16, 2304900. [Google Scholar] [CrossRef]
  21. Hoseini Tavassol, Z.; Ejtahed, H.S.; Atlasi, R.; Saghafian, F.; Khalagi, K.; Hasani-Ranjbar, S.; Siadat, S.D.; Nabipour, I.; Ostovar, A.; Larijani, B. Alteration in Gut Microbiota Composition of Older Adults Is Associated with Obesity and Its Indices: A Systematic Review. J. Nutr. Health Aging 2023, 27, 817–823. [Google Scholar] [CrossRef]
  22. Lippert, K.; Kedenko, L.; Antonielli, L.; Kedenko, I.; Gemeier, C.; Leitner, M.; Kautzky-Willer, A.; Paulweber, B.; Hackl, E. Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. Benef. Microbes 2017, 8, 545–556. [Google Scholar] [CrossRef]
  23. Nishijima, S.; Suda, W.; Oshima, K.; Kim, S.-W.; Hirose, Y.; Morita, H.; Hattori, M. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016, 23, 125–133. [Google Scholar] [CrossRef] [PubMed]
  24. Bamberger, C.; Rossmeier, A.; Lechner, K.; Wu, L.; Waldmann, E.; Fischer, S.; Stark, R.G.; Altenhofer, J.; Henze, K.; Parhofer, K.G. A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial. Nutrients 2018, 10, 244. [Google Scholar] [CrossRef] [PubMed]
  25. Ozato, N.; Saito, S.; Yamaguchi, T.; Katashima, M.; Tokuda, I.; Sawada, K.; Katsuragi, Y.; Kakuta, M.; Imoto, S.; Ihara, K.; et al. Blautia genus associated with visceral fat accumulation in adults 20–76 years of age. NPJ Biofilms Microbiomes 2019, 5, 28. [Google Scholar] [CrossRef]
  26. Liu, C.; Finegold, S.M.; Song, Y.; Lawson, P.A. Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydrogenotrophica comb. nov., Blautia luti comb. nov., Blautia producta comb. nov., Blautia schinkii comb. nov. and description of Blautia wexlerae sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2008, 58, 1896–1902. [Google Scholar] [CrossRef] [PubMed]
  27. Ozato, N.; Yamaguchi, T.; Mori, K.; Katashima, M.; Kumagai, M.; Murashita, K.; Katsuragi, Y.; Tamada, Y.; Kakuta, M.; Imoto, S.; et al. Two Blautia Species Associated with Visceral Fat Accumulation: A One-Year Longitudinal Study. Biology 2022, 11, 318. [Google Scholar] [CrossRef]
  28. Hosomi, K.; Saito, M.; Park, J.; Murakami, H.; Shibata, N.; Ando, M.; Nagatake, T.; Konishi, K.; Ohno, H.; Tanisawa, K.; et al. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. Nat. Commun. 2022, 13, 4477. [Google Scholar] [CrossRef] [PubMed]
  29. Benítez-Páez, A.; Gómez Del Pugar, E.M.; López-Almela, I.; Moya-Pérez, Á.; Codoñer-Franch, P.; Sanz, Y. Depletion of Blautia Species in the Microbiota of Obese Children Relates to Intestinal Inflammation and Metabolic Phenotype Worsening. mSystems 2020, 5. [Google Scholar] [CrossRef]
  30. Wu, X.R.; Chen, Z.Z.; Dong, X.L.; Zhao, Q.P.; Cai, J. A Novel Symbiotic Formulation Reduces Obesity and Concomitant Metabolic Syndrome in Rats by Raising the Relative Abundance of Blautia. Nutrients 2023, 15, 956. [Google Scholar] [CrossRef]
  31. Xing, H.; Zhang, Y.; Krämer, M.; Kissmann, A.K.; Henkel, M.; Weil, T.; Knippschild, U.; Rosenau, F. A Polyclonal Selex Aptamer Library Directly Allows Specific Labelling of the Human Gut Bacterium Blautia producta without Isolating Individual Aptamers. Molecules 2022, 27, 5693. [Google Scholar] [CrossRef]
  32. Vazquez-Moreno, M.; Perez-Herrera, A.; Locia-Morales, D.; Dizzel, S.; Meyre, D.; Stearns, J.C.; Cruz, M. Association of gut microbiome with fasting triglycerides, fasting insulin and obesity status in Mexican children. Pediatr. Obes. 2021, 16, e12748. [Google Scholar] [CrossRef] [PubMed]
  33. Wei, Y.; Liang, J.; Su, Y.; Wang, J.; Amakye, W.K.; Pan, J.; Chu, X.; Ma, B.; Song, Y.; Li, Y.; et al. The associations of the gut microbiome composition and short-chain fatty acid concentrations with body fat distribution in children. Clin. Nutr. 2021, 40, 3379–3390. [Google Scholar] [CrossRef] [PubMed]
  34. Dai, D.; Zhu, J.; Sun, C.; Li, M.; Liu, J.; Wu, S.; Ning, K.; He, L.-J.; Zhao, X.-M.; Chen, W.-H. GMrepo v2: A curated human gut microbiome database with special focus on disease markers and cross-dataset comparison. Nucleic Acids Res. 2021, 50, D777–D784. [Google Scholar] [CrossRef]
  35. Wu, S.; Sun, C.; Li, Y.; Wang, T.; Jia, L.; Lai, S.; Yang, Y.; Luo, P.; Dai, D.; Yang, Y.-Q.; et al. GMrepo: A database of curated and consistently annotated human gut metagenomes. Nucleic Acids Res. 2019, 48, D545–D553. [Google Scholar] [CrossRef]
  36. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
  37. O’Connor, A.M.; Sargeant, J.M. Critical Appraisal of Studies Using Laboratory Animal Models. ILAR J. 2014, 55, 405–417. [Google Scholar] [CrossRef]
  38. Higgins, J.P.T.; Altman, D.G. Assessing Risk of Bias in Included Studies. In Cochrane Handbook for Systematic Reviews of Interventions; Higgins, J.P., Green, S., Eds.; WILEY Online Library: Hoboken, NJ, USA, 2008; pp. 187–241. [Google Scholar] [CrossRef]
  39. Ďásková, N.; Modos, I.; Krbcová, M.; Kuzma, M.; Pelantová, H.; Hradecký, J.; Heczková, M.; Bratová, M.; Videňská, P.; Šplíchalová, P.; et al. Multi-omics signatures in new-onset diabetes predict metabolic response to dietary inulin: Findings from an observational study followed by an interventional trial. Nutr. Diabetes 2023, 13, 7. [Google Scholar] [CrossRef] [PubMed]
  40. Gu, I.; Lam, W.S.; Marasini, D.; Brownmiller, C.; Savary, B.J.; Lee, J.A.; Carbonero, F.; Lee, S.O. In Vitro Fecal Fermentation Patterns of Arabinoxylan from Rice Bran on Fecal Microbiota from Normal-Weight and Overweight/Obese Subjects. Nutrients 2021, 13, 2052. [Google Scholar] [CrossRef]
  41. Mei, X.; Li, Y.; Zhang, X.; Zhai, X.; Yang, Y.; Li, Z.; Li, L. Maternal Phlorizin Intake Protects Offspring from Maternal Obesity-Induced Metabolic Disorders in Mice via Targeting Gut Microbiota to Activate the SCFA-GPR43 Pathway. J. Agric. Food Chem. 2024, 72, 4703–4725. [Google Scholar] [CrossRef]
  42. Gómez-Pérez, A.M.; Ruiz-Limón, P.; Salas-Salvadó, J.; Vioque, J.; Corella, D.; Fitó, M.; Vidal, J.; Atzeni, A.; Torres-Collado, L.; Álvarez-Sala, A.; et al. Gut microbiota in nonalcoholic fatty liver disease: A PREDIMED-Plus trial sub analysis. Gut Microbes 2023, 15, 2223339. [Google Scholar] [CrossRef]
  43. Sánchez-Alcoholado, L.; Gutiérrez-Repiso, C.; Gómez-Pérez, A.M.; García-Fuentes, E.; Tinahones, F.J.; Moreno-Indias, I. Gut microbiota adaptation after weight loss by Roux-en-Y gastric bypass or sleeve gastrectomy bariatric surgeries. Surg. Obes. Relat. Dis. 2019, 15, 1888–1895. [Google Scholar] [CrossRef]
  44. O’Neill, L.; Pandya, V.; Grigoryan, Z.; Patel, R.; DeSipio, J.; Judge, T.; Phadtare, S. Effects of Milkfat on the Gut Microbiome of Patients After Bariatric Surgery, a Pilot Study. Obes. Surg. 2022, 32, 480–488. [Google Scholar] [CrossRef] [PubMed]
  45. Pérez-Rubio, Á.; Soluyanova, P.; Moro, E.; Quintás, G.; Rienda, I.; Periañez, M.D.; Painel, A.; Vizuete, J.; Pérez-Rojas, J.; Castell, J.V.; et al. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients. Nutrients 2023, 15, 3187. [Google Scholar] [CrossRef] [PubMed]
  46. Sun, S.; Lei, O.K.; Nie, J.; Shi, Q.; Xu, Y.; Kong, Z. Effects of Low-Carbohydrate Diet and Exercise Training on Gut Microbiota. Front. Nutr. 2022, 9, 884550. [Google Scholar] [CrossRef] [PubMed]
  47. Lee, A.; Jeon, K.J.; Kim, H.K.; Han, S.N. Effect of a 12-week weight management program on the clinical characteristics and dietary intake of the young obese and the contributing factors to the successful weight loss. Nutr. Res. Pract. 2014, 8, 571–579. [Google Scholar] [CrossRef] [PubMed]
  48. Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M.C.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 2022, 387, 205–216. [Google Scholar] [CrossRef] [PubMed]
  49. Yadav, J.; Liang, T.; Qin, T.; Nathan, N.; Schwenger, K.J.P.; Pickel, L.; Xie, L.; Lei, H.; Winer, D.A.; Maughan, H.; et al. Gut microbiome modified by bariatric surgery improves insulin sensitivity and correlates with increased brown fat activity and energy expenditure. Cell Rep. Med. 2023, 4, 101051. [Google Scholar] [CrossRef]
  50. Gasmi, A.; Bjørklund, G.; Mujawdiya, P.K.; Semenova, Y.; Dosa, A.; Piscopo, S.; Pen, J.J.; Gasmi Benahmed, A.; Costea, D.O. Gut microbiota in bariatric surgery. Crit. Rev. Food Sci. Nutr. 2023, 63, 9299–9314. [Google Scholar] [CrossRef]
  51. Ocaña-Wilhelmi, L.; Martín-Núñez, G.M.; Ruiz-Limón, P.; Alcaide, J.; García-Fuentes, E.; Gutiérrez-Repiso, C.; Tinahones, F.J.; Moreno-Indias, I. Gut Microbiota Metabolism of Bile Acids Could Contribute to the Bariatric Surgery Improvements in Extreme Obesity. Metabolites 2021, 11, 733. [Google Scholar] [CrossRef]
  52. Lin, W.; Wen, L.; Wen, J.; Xiang, G. Effects of Sleeve Gastrectomy on Fecal Gut Microbiota and Short-Chain Fatty Acid Content in a Rat Model of Polycystic Ovary Syndrome. Front. Endocrinol. 2021, 12, 747888. [Google Scholar] [CrossRef]
  53. Haal, S.; Guman, M.S.S.; de Brauw, L.M.; van Veen, R.N.; Schouten, R.; Fockens, P.; Gerdes, V.E.A.; Dijkgraaf, M.G.W.; Voermans, R.P. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: Statistical analysis plan for a randomised controlled trial (UPGRADE trial). Trials 2020, 21, 676. [Google Scholar] [CrossRef] [PubMed]
  54. Jie, Z.; Yu, X.; Liu, Y.; Sun, L.; Chen, P.; Ding, Q.; Gao, Y.; Zhang, X.; Yu, M.; Liu, Y.; et al. The Baseline Gut Microbiota Directs Dieting-Induced Weight Loss Trajectories. Gastroenterology 2021, 160, 2029–2042.e16. [Google Scholar] [CrossRef]
  55. Cuevas-Sierra, A.; Milagro, F.I.; Guruceaga, E.; Cuervo, M.; Goni, L.; García-Granero, M.; Martinez, J.A.; Riezu-Boj, J.I. A weight-loss model based on baseline microbiota and genetic scores for selection of dietary treatments in overweight and obese population. Clin. Nutr. 2022, 41, 1712–1723. [Google Scholar] [CrossRef]
  56. Wang, H.; Lv, X.; Zhao, S.; Yuan, W.; Zhou, Q.; Sadiq, F.A.; Zhao, J.; Lu, W.; Wu, W. Weight Loss Promotion in Individuals with Obesity through Gut Microbiota Alterations with a Multiphase Modified Ketogenic Diet. Nutrients 2023, 15, 4163. [Google Scholar] [CrossRef] [PubMed]
  57. Pataky, Z.; Genton, L.; Spahr, L.; Lazarevic, V.; Terraz, S.; Gaïa, N.; Rubbia-Brandt, L.; Golay, A.; Schrenzel, J.; Pichard, C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig. Dis. Sci. 2016, 61, 2721–2731. [Google Scholar] [CrossRef] [PubMed]
  58. Yuan, W.; Lu, W.; Wang, H.; Wu, W.; Zhou, Q.; Chen, Y.; Lee, Y.K.; Zhao, J.; Zhang, H.; Chen, W. A multiphase dietetic protocol incorporating an improved ketogenic diet enhances weight loss and alters the gut microbiome of obese people. Int. J. Food Sci. Nutr. 2022, 73, 238–250. [Google Scholar] [CrossRef] [PubMed]
  59. Wang, H.; Song, W.; Yuan, W.; Zhou, Q.; Sadiq, F.A.; Zhao, J.; Wu, W.; Lu, W. Modulating the Human Gut Microbiota through Hypocaloric Balanced Diets: An Effective Approach for Managing Obesity. Nutrients 2023, 15, 3101. [Google Scholar] [CrossRef]
  60. Medawar, E.; Haange, S.B.; Rolle-Kampczyk, U.; Engelmann, B.; Dietrich, A.; Thieleking, R.; Wiegank, C.; Fries, C.; Horstmann, A.; Villringer, A.; et al. Gut microbiota link dietary fiber intake and short-chain fatty acid metabolism with eating behavior. Transl. Psychiatry 2021, 11, 500. [Google Scholar] [CrossRef]
  61. Rettedal, E.A.; Cree, J.M.E.; Adams, S.E.; MacRae, C.; Skidmore, P.M.L.; Cameron-Smith, D.; Gant, N.; Blenkiron, C.; Merry, T.L. Short-term high-intensity interval training exercise does not affect gut bacterial community diversity or composition of lean and overweight men. Exp. Physiol. 2020, 105, 1268–1279. [Google Scholar] [CrossRef]
  62. Quiroga, R.; Nistal, E.; Estébanez, B.; Porras, D.; Juárez-Fernández, M.; Martínez-Flórez, S.; García-Mediavilla, M.V.; de Paz, J.A.; González-Gallego, J.; Sánchez-Campos, S.; et al. Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. Exp. Mol. Med. 2020, 52, 1048–1061. [Google Scholar] [CrossRef]
  63. Matei, D.; Trofin, D.; Iordan, D.A.; Onu, I.; Condurache, I.; Ionite, C.; Buculei, I. The Endocannabinoid System and Physical Exercise. Int. J. Mol. Sci. 2023, 24, 1989. [Google Scholar] [CrossRef]
  64. Meyer, J.D.; Crombie, K.M.; Cook, D.B.; Hillard, C.J.; Koltyn, K.F. Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder. Med. Sci. Sports Exerc. 2019, 51, 1909–1917. [Google Scholar] [CrossRef]
  65. Di Marzo, V.; Després, J.-P. CB1 antagonists for obesity—What lessons have we learned from rimonabant? Nat. Rev. Endocrinol. 2009, 5, 633–638. [Google Scholar] [CrossRef] [PubMed]
  66. Alhouayek, M.; Muccioli, G.G. Harnessing the anti-inflammatory potential of palmitoylethanolamide. Drug Discov. Today 2014, 19, 1632–1639. [Google Scholar] [CrossRef]
  67. Couch, D.G.; Cook, H.; Ortori, C.; Barrett, D.; Lund, J.N.; O’Sullivan, S.E. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm. Bowel Dis. 2019, 25, 1006–1018. [Google Scholar] [CrossRef]
  68. Minichino, A.; Jackson, M.A.; Francesconi, M.; Steves, C.J.; Menni, C.; Burnet, P.W.J.; Lennox, B.R. Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort. Mol. Psychiatry 2021, 26, 6269–6276. [Google Scholar] [CrossRef] [PubMed]
  69. Holmberg, S.M.; Feeney, R.H.; Prasoodanan, P.K.V.; Puértolas-Balint, F.; Singh, D.K.; Wongkuna, S.; Zandbergen, L.; Hauner, H.; Brandl, B.; Nieminen, A.I.; et al. The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids. Nat. Commun. 2024, 15, 3502. [Google Scholar] [CrossRef] [PubMed]
  70. Rashidi, A.; Peled, J.U.; Ebadi, M.; Rehman, T.U.; Elhusseini, H.; Marcello, L.T.; Halaweish, H.; Kaiser, T.; Holtan, S.G.; Khoruts, A.; et al. Protective Effect of Intestinal Blautia Against Neutropenic Fever in Allogeneic Transplant Recipients. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2022, 75, 1912–1920. [Google Scholar] [CrossRef]
  71. Zhao, K.; Qiu, L.; He, Y.; Tao, X.; Zhang, Z.; Wei, H. Alleviation Syndrome of High-Cholesterol-Diet-Induced Hypercholesterolemia in Mice by Intervention with Lactiplantibacillus plantarum WLPL21 via Regulation of Cholesterol Metabolism and Transportation as Well as Gut Microbiota. Nutrients 2023, 15, 2600. [Google Scholar] [CrossRef]
  72. Yan, J.; Li, J.; Xue, Q.; Xie, S.; Jiang, J.; Li, P.; Du, B. Bacillus sp. DU-106 ameliorates type 2 diabetes by modulating gut microbiota in high-fat-fed and streptozotocin-induced mice. J. Appl. Microbiol. 2022, 133, 3126–3138. [Google Scholar] [CrossRef]
  73. Larsen, N.; Vogensen, F.K.; Gøbel, R.J.; Michaelsen, K.F.; Forssten, S.D.; Lahtinen, S.J.; Jakobsen, M. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin. Nutr. 2013, 32, 935–940. [Google Scholar] [CrossRef]
  74. Shibata, M.; Ozato, N.; Tsuda, H.; Mori, K.; Kinoshita, K.; Katashima, M.; Katsuragi, Y.; Nakaji, S.; Maeda, H. Mouse Model of Anti-Obesity Effects of Blautia hansenii on Diet-Induced Obesity. Curr. Issues Mol. Biol. 2023, 45, 7147–7160. [Google Scholar] [CrossRef] [PubMed]
  75. Bäumler, A.J.; Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 2016, 535, 85–93. [Google Scholar] [CrossRef]
  76. Li, Y.; Liu, W.; Xu, Z.Z.; Xiao, J.X.; Zong, A.Z.; Qiu, B.; Jia, M.; Liu, L.N.; Xu, T.C. Research on the mechanism of microwave-toughened starch on glucolipid metabolism in mice. Food Funct. 2020, 11, 9789–9800. [Google Scholar] [CrossRef] [PubMed]
  77. Song, J.; Liu, Q.; Hao, M.; Zhai, X.; Chen, J. Effects of neutral polysaccharide from Platycodon grandiflorum on high-fat diet-induced obesity via the regulation of gut microbiota and metabolites. Front. Endocrinol. 2023, 14, 1078593. [Google Scholar] [CrossRef]
  78. Kim, Y.; Han, H.; Oh, Y.; Shin, H.; Park, G.; Park, S.; Manthey, J.A.; Kim, Y.; Kim, Y. A combination of rebaudioside A and neohesperidin dihydrochalcone suppressed weight gain by regulating visceral fat and hepatic lipid metabolism in ob/ob mice. Food Sci. Biotechnol. 2024, 33, 913–923. [Google Scholar] [CrossRef]
  79. Guzzardi, M.A.; Ederveen, T.H.A.; Rizzo, F.; Weisz, A.; Collado, M.C.; Muratori, F.; Gross, G.; Alkema, W.; Iozzo, P. Maternal pre-pregnancy overweight and neonatal gut bacterial colonization are associated with cognitive development and gut microbiota composition in pre-school-age offspring. Brain Behav. Immun. 2022, 100, 311–320. [Google Scholar] [CrossRef] [PubMed]
  80. Lahtinen, P.; Juuti, A.; Luostarinen, M.; Niskanen, L.; Liukkonen, T.; Tillonen, J.; Kössi, J.; Ilvesmäki, V.; Viljakka, M.; Satokari, R.; et al. Effectiveness of Fecal Microbiota Transplantation for Weight Loss in Patients With Obesity Undergoing Bariatric Surgery: A Randomized Clinical Trial. JAMA Netw. Open 2022, 5, e2247226. [Google Scholar] [CrossRef] [PubMed]
  81. Ghorbani, Y.; Schwenger, K.J.P.; Sharma, D.; Jung, H.; Yadav, J.; Xu, W.; Lou, W.; Poutanen, S.; Hota, S.S.; Comelli, E.M.; et al. Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double-blind, placebo-controlled Phase 2 trial. Diabetes Obes. Metab. 2023, 25, 479–490. [Google Scholar] [CrossRef]
  82. Zhang, Z.; Mocanu, V.; Cai, C.; Dang, J.; Slater, L.; Deehan, E.C.; Walter, J.; Madsen, K.L. Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome—A Systematic Review. Nutrients 2019, 11, 2291. [Google Scholar] [CrossRef]
  83. Becetti, I.; Lauze, M.; Lee, H.; Bredella, M.A.; Misra, M.; Singhal, V. Changes in Branched-Chain Amino Acids One Year after Sleeve Gastrectomy in Youth with Obesity and Their Association with Changes in Insulin Resistance. Nutrients 2023, 15, 3801. [Google Scholar] [CrossRef]
  84. Kitsy, A.; Carney, S.; Vivar, J.C.; Knight, M.S.; Pointer, M.A.; Gwathmey, J.K.; Ghosh, S. Effects of Leucine Supplementation and Serum Withdrawal on Branched-Chain Amino Acid Pathway Gene and Protein Expression in Mouse Adipocytes. PLoS ONE 2014, 9, e102615. [Google Scholar] [CrossRef] [PubMed]
  85. Melnik, B.C. Leucine signaling in the pathogenesis of type 2 diabetes and obesity. World J. Diabetes 2012, 3, 38–53. [Google Scholar] [CrossRef]
  86. Lee, Y.; Cho, J.Y.; Cho, K.Y. Serum, Urine, and Fecal Metabolome Alterations in the Gut Microbiota in Response to Lifestyle Interventions in Pediatric Obesity: A Non-Randomized Clinical Trial. Nutrients 2023, 15, 2184. [Google Scholar] [CrossRef]
  87. Liu, X.; Mao, B.; Gu, J.; Wu, J.; Cui, S.; Wang, G.; Zhao, J.; Zhang, H.; Chen, W. Blautia—A new functional genus with potential probiotic properties? Gut Microbes 2021, 13, 1875796. [Google Scholar] [CrossRef]
  88. Yuan, X.; Zhang, Y.; Lin, X.; Yang, X.; Chen, R. Association of gut microbiota and glucose metabolism in children with disparate degrees of adiposity. Pediatr. Obes. 2023, 18, e13009. [Google Scholar] [CrossRef] [PubMed]
  89. Cho, K.Y. Association of gut microbiota with obesity in children and adolescents. Clin. Exp. Pediatr. 2023, 66, 148–154. [Google Scholar] [CrossRef]
  90. Galley, J.D.; Bailey, M.; Dush, C.K.; Schoppe-Sullivan, S.; Christian, L.M. Maternal obesity is associated with alterations in the gut microbiome in toddlers. PLoS ONE 2014, 9, e113026. [Google Scholar] [CrossRef]
  91. Squillario, M.; Bonaretti, C.; La Valle, A.; Di Marco, E.; Piccolo, G.; Minuto, N.; Patti, G.; Napoli, F.; Bassi, M.; Maghnie, M.; et al. Gut-microbiota in children and adolescents with obesity: Inferred functional analysis and machine-learning algorithms to classify microorganisms. Sci. Rep. 2023, 13, 11294. [Google Scholar] [CrossRef]
  92. Ruiz, A.; Cerdó, T.; Jáuregui, R.; Pieper, D.H.; Marcos, A.; Clemente, A.; García, F.; Margolles, A.; Ferrer, M.; Campoy, C.; et al. One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. Environ. Microbiol. 2017, 19, 1536–1551. [Google Scholar] [CrossRef] [PubMed]
  93. Morgado, M.C.; Sousa, M.; Coelho, A.B.; Costa, J.A.; Seabra, A. Exploring Gut Microbiota and the Influence of Physical Activity Interventions on Overweight and Obese Children and Adolescents: A Systematic Review. Healthcare 2023, 11, 2459. [Google Scholar] [CrossRef] [PubMed]
  94. Kasai, C.; Sugimoto, K.; Moritani, I.; Tanaka, J.; Oya, Y.; Inoue, H.; Tameda, M.; Shiraki, K.; Ito, M.; Takei, Y.; et al. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol. 2015, 15, 100. [Google Scholar] [CrossRef] [PubMed]
  95. Liu, C.; Li, J.; Zhang, Y.; Philip, A.; Shi, E.; Chi, X.; Meng, J. Influence of glucose fermentation on CO2 assimilation to acetate in homoacetogen Blautia coccoides GA-1. J. Ind. Microbiol. Biotechnol. 2015, 42, 1217–1224. [Google Scholar] [CrossRef]
  96. Ang, Z.; Ding, J.L. GPR41 and GPR43 in Obesity and Inflammation–Protective or Causative? Front. Immunol. 2016, 7, 28. [Google Scholar] [CrossRef]
  97. Kimura, I.; Ozawa, K.; Inoue, D.; Imamura, T.; Kimura, K.; Maeda, T.; Terasawa, K.; Kashihara, D.; Hirano, K.; Tani, T. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat. Commun. 2013, 4, 1829. [Google Scholar] [CrossRef]
  98. Mo, R.; Zhang, M.; Wang, H.; Liu, T.; Zhang, G.; Wu, Y. Short-term changes in dietary fat levels and starch sources affect weight management, glucose and lipid metabolism, and gut microbiota in adult cats. J. Anim. Sci. 2023, 101, skad276. [Google Scholar] [CrossRef] [PubMed]
  99. Freitas, R.; Vasques, A.C.J.; Fernandes, G.D.R.; Ribeiro, F.B.; Solar, I.; Barbosa, M.G.; Pititto, B.A.; Geloneze, B.; Ferreira, S.R.G. Associations of Blautia Genus With Early-Life Events and Later Phenotype in the NutriHS. Front. Cell Infect. Microbiol. 2022, 12, 838750. [Google Scholar] [CrossRef] [PubMed]
  100. Radjabzadeh, D.; Boer, C.G.; Beth, S.A.; van der Wal, P.; Kiefte-De Jong, J.C.; Jansen, M.A.E.; Konstantinov, S.R.; Peppelenbosch, M.P.; Hays, J.P.; Jaddoe, V.W.V.; et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Sci. Rep. 2020, 10, 1040. [Google Scholar] [CrossRef]
  101. Hassan, N.E.; El Shebini, S.M.; El-Masry, S.A.; Ahmed, N.H.; Kamal, A.N.; Ismail, A.S.; Alian, K.M.; Mostafa, M.I.; Selim, M.; Afify, M.A.S. Brief overview of dietary intake, some types of gut microbiota, metabolic markers and research opportunities in sample of Egyptian women. Sci. Rep. 2022, 12, 17291. [Google Scholar] [CrossRef]
  102. Kusnadi, Y.; Saleh, M.I.; Ali, Z.; Hermansyah, H.; Murti, K.; Hafy, Z.; Yuristo, N.S.E. Firmicutes/Bacteroidetes Ratio of Gut Microbiota and Its Relationships with Clinical Parameters of Type 2 Diabetes Mellitus: A Systematic Review. Open Access Maced. J. Med. Sci. 2023, 11, 67–72. [Google Scholar] [CrossRef]
  103. Magne, F.; Gotteland, M.; Gauthier, L.; Zazueta, A.; Pesoa, S.; Navarrete, P.; Balamurugan, R. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients 2020, 12, 1474. [Google Scholar] [CrossRef] [PubMed]
  104. Burakova, I.; Smirnova, Y.; Gryaznova, M.; Syromyatnikov, M.; Chizhkov, P.; Popov, E.; Popov, V. The Effect of Short-Term Consumption of Lactic Acid Bacteria on the Gut Microbiota in Obese People. Nutrients 2022, 14, 3384. [Google Scholar] [CrossRef]
  105. Mao, K.; Gao, J.; Wang, X.; Li, X.; Geng, S.; Zhang, T.; Sadiq, F.A.; Sang, Y. Bifidobacterium animalis subsp. lactis BB-12 Has Effect Against Obesity by Regulating Gut Microbiota in Two Phases in Human Microbiota-Associated Rats. Front. Nutr. 2022, 8, 811619. [Google Scholar] [CrossRef]
  106. Hitch, T.C.A.; Riedel, T.; Oren, A.; Overmann, J.; Lawley, T.D.; Clavel, T. Automated analysis of genomic sequences facilitates high-throughput and comprehensive description of bacteria. ISME Commun. 2021, 1, 16. [Google Scholar] [CrossRef] [PubMed]
  107. Paek, J.; Shin, Y.; Kook, J.K.; Chang, Y.H. Blautia argi sp. nov., a new anaerobic bacterium isolated from dog faeces. Int. J. Syst. Evol. Microbiol. 2019, 69, 33–38. [Google Scholar] [CrossRef]
  108. Lagkouvardos, I.; Pukall, R.; Abt, B.; Foesel, B.U.; Meier-Kolthoff, J.P.; Kumar, N.; Bresciani, A.; Martínez, I.; Just, S.; Ziegler, C.; et al. The Mouse Intestinal Bacterial Collection (miBC) provides host-specific insight into cultured diversity and functional potential of the gut microbiota. Nat. Microbiol. 2016, 1, 16131. [Google Scholar] [CrossRef]
  109. Liu, C.; Du, M.X.; Abuduaini, R.; Yu, H.Y.; Li, D.H.; Wang, Y.J.; Zhou, N.; Jiang, M.Z.; Niu, P.X.; Han, S.S.; et al. Correction: Enlightening the taxonomy darkness of human gut microbiomes with a cultured biobank. Microbiome 2022, 10, 163. [Google Scholar] [CrossRef]
  110. Kaneuchi, C.; Benno, Y.; Mitsuoka, T. Clostridium coccoides, a New Species from the Feces of Mice. Int. J. Syst. Evol. Microbiol. 1976, 26, 482–486. [Google Scholar] [CrossRef]
  111. Kim, J.-S.; Park, J.-E.; Lee, K.C.; Choi, S.-H.; Oh, B.S.; Yu, S.Y.; Eom, M.K.; Kang, S.W.; Han, K.-I.; Suh, M.K.; et al. Blautia faecicola sp. nov., isolated from faeces from a healthy human. Int. J. Syst. Evol. Microbiol. 2020, 70, 2059–2065. [Google Scholar] [CrossRef]
  112. Park, S.K.; Kim, M.S.; Bae, J.W. Blautia faecis sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2013, 63, 599–603. [Google Scholar] [CrossRef]
  113. Afrizal, A.; Hitch, T.C.A.; Viehof, A.; Treichel, N.; Riedel, T.; Abt, B.; Buhl, E.M.; Kohlheyer, D.; Overmann, J.; Clavel, T. Anaerobic single-cell dispensing facilitates the cultivation of human gut bacteria. Environ. Microbiol. 2022, 24, 3861–3881. [Google Scholar] [CrossRef]
  114. Furuya, H.; Ide, Y.; Hamamoto, M.; Asanuma, N.; Hino, T. Isolation of a novel bacterium, Blautia glucerasei sp. nov., hydrolyzing plant glucosylceramide to ceramide. Arch. Microbiol. 2010, 192, 365–372. [Google Scholar] [CrossRef] [PubMed]
  115. Holdeman, L.V.; Moore, W.E.C. New Genus, Coprococcus, Twelve New Species, and Emended Descriptions of Four Previously Described Species of Bacteria from Human Feces. Int. J. Syst. Evol. Microbiol. 1974, 24, 260–277. [Google Scholar] [CrossRef]
  116. Shin, N.R.; Kang, W.; Tak, E.J.; Hyun, D.W.; Kim, P.S.; Kim, H.S.; Lee, J.Y.; Sung, H.; Whon, T.W.; Bae, J.W. Blautia hominis sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2018, 68, 1059–1064. [Google Scholar] [CrossRef] [PubMed]
  117. Bernalier, A.; Willems, A.; Leclerc, M.; Rochet, V.; Collins, M.D. Ruminococcus hydrogenotrophicus sp. nov., a new H2/CO2-utilizing acetogenic bacterium isolated from human feces. Arch. Microbiol. 1996, 166, 176–183. [Google Scholar] [CrossRef] [PubMed]
  118. Wang, Y.J.; Abdugheni, R.; Liu, C.; Zhou, N.; You, X.; Liu, S.J. Blautia intestinalis sp. nov., isolated from human feces. Int. J. Syst. Evol. Microbiol. 2021, 71, 005005. [Google Scholar] [CrossRef]
  119. Lu, L.F.; Yang, Y.; Chai, L.J.; Lu, Z.M.; Zhang, L.Q.; Qin, H.; Yang, P.; Xu, Z.H.; Shen, C.H. Blautia liquoris sp. nov., isolated from the mud in a fermentation cellar used for the production of Chinese strong-flavour liquor. Int. J. Syst. Evol. Microbiol. 2021, 71, 005041. [Google Scholar] [CrossRef]
  120. Simmering, R.; Taras, D.; Schwiertz, A.; Le Blay, G.; Gruhl, B.; Lawson, P.A.; Collins, M.D.; Blaut, M. Ruminococcus luti sp. nov., isolated from a human faecal sample. Syst. Appl. Microbiol. 2002, 25, 189–193. [Google Scholar] [CrossRef]
  121. Moore, W.E.C.; Johnson, J.L.; Holdeman, L.V. Emendation of Bacteroidaceae and Butyrivibrio and Descriptions of Desulfomonas gen. nov. and Ten New Species in the Genera Desulfomonas, Butyrivibrio, Eubacterium, Clostridium, and Ruminococcus. Int. J. Syst. Evol. Microbiol. 1976, 26, 238–252. [Google Scholar] [CrossRef]
  122. Lawson, P.A.; Finegold, S.M. Reclassification of Ruminococcus obeum as Blautia obeum comb. nov. Int. J. Syst. Evol. Microbiol. 2015, 65, 789–793. [Google Scholar] [CrossRef]
  123. Miura, T.; Shimamura, M.; Yamazoe, A.; Kawasaki, H. Blautia parvula sp. nov., isolated from Japanese faecal samples. Int. J. Syst. Evol. Microbiol. 2023, 73, 005871. [Google Scholar] [CrossRef] [PubMed]
  124. Maturana, J.L.; Cárdenas, J.P. Insights on the Evolutionary Genomics of the Blautia Genus: Potential New Species and Genetic Content Among Lineages. Front. Microbiol. 2021, 12, 660920. [Google Scholar] [CrossRef] [PubMed]
  125. Rieu-Lesme, F.; Morvan, B.; Collins, M.D.; Fonty, G.; Willems, A. A new H2/CO2-using acetogenic bacterium from the rumen: Description of Ruminococcus schinkii sp. nov. FEMS Microbiol. Lett. 1996, 140, 281–286. [Google Scholar] [CrossRef] [PubMed]
  126. Park, S.K.; Kim, M.S.; Roh, S.W.; Bae, J.W. Blautia stercoris sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2012, 62, 776–779. [Google Scholar] [CrossRef]
Microorganisms 12 01768 g002
Figure 2. Study selection flowchart following the PRISMA guidelines (A), and proportions of the selected variables from in vivo and clinical studies ((B), n = 170).
Figure 2. Study selection flowchart following the PRISMA guidelines (A), and proportions of the selected variables from in vivo and clinical studies ((B), n = 170).
Microorganisms 12 01768 g002
Microorganisms 12 01768 g003
Figure 3. (A) Effect of prebiotics on Blautia, and (B) the relative abundance of selected bacteria from the most and least dominant bacterial taxa in infant fecal samples at ages 0 (first pass meconium), 3, 6, 12, and 36 months. Panel A shows the types of prebiotics in green and red boxes that increased (green arrow) and reduced (red arrow) the abundance of Blautia in their respective animal and human subjects that subsequently improved obesity. Note that the obesity-ameliorating effects of some prebiotic products in both green and red boxes were observed in in vivo studies, but the human pictures in the figure were used as representations of obesity and normal weight. Panel B shows a line graph indicating the significant presence of Blautia in meconium samples, which decreased substantially at month 3, followed by a steady increase from month 6 to month 36 (This figure was generated from the Supplementary Dataset of Ref. [79].).
Figure 3. (A) Effect of prebiotics on Blautia, and (B) the relative abundance of selected bacteria from the most and least dominant bacterial taxa in infant fecal samples at ages 0 (first pass meconium), 3, 6, 12, and 36 months. Panel A shows the types of prebiotics in green and red boxes that increased (green arrow) and reduced (red arrow) the abundance of Blautia in their respective animal and human subjects that subsequently improved obesity. Note that the obesity-ameliorating effects of some prebiotic products in both green and red boxes were observed in in vivo studies, but the human pictures in the figure were used as representations of obesity and normal weight. Panel B shows a line graph indicating the significant presence of Blautia in meconium samples, which decreased substantially at month 3, followed by a steady increase from month 6 to month 36 (This figure was generated from the Supplementary Dataset of Ref. [79].).
Microorganisms 12 01768 g003
Microorganisms 12 01768 g004
Figure 4. Blautia status in adult participants (n = 53).
Figure 4. Blautia status in adult participants (n = 53).
Microorganisms 12 01768 g004
Microorganisms 12 01768 g005
Figure 5. Factors influencing the abundance of Blautia in the gut. The proliferation of members of the genus Blautia or specific species (Box 1) and the reduction of certain compounds (Box 3), either independently or synergistically, produce important metabolites (Box 2) that may help alleviate obesity (green lines). However, unclear events lead to an increased abundance of some un-speciated Blautia associated with obesity (yellow lines). Additionally, factors inhibiting Blautia abundance (Box 4) may exacerbate obesity (red dotted lines). Note that the effect of a cornstarch diet on Blautia has only been reported in cats [98], so caution should be taken when extrapolating these findings to humans. Also, note that the obesity-ameliorating effects of some interventions were observed in in vivo studies; the human images in the figure are used as representations of obesity and normal weight.
Figure 5. Factors influencing the abundance of Blautia in the gut. The proliferation of members of the genus Blautia or specific species (Box 1) and the reduction of certain compounds (Box 3), either independently or synergistically, produce important metabolites (Box 2) that may help alleviate obesity (green lines). However, unclear events lead to an increased abundance of some un-speciated Blautia associated with obesity (yellow lines). Additionally, factors inhibiting Blautia abundance (Box 4) may exacerbate obesity (red dotted lines). Note that the effect of a cornstarch diet on Blautia has only been reported in cats [98], so caution should be taken when extrapolating these findings to humans. Also, note that the obesity-ameliorating effects of some interventions were observed in in vivo studies; the human images in the figure are used as representations of obesity and normal weight.
Microorganisms 12 01768 g005
Table 1. Blautia response in gut microbiota changes due to diet in adult subjects.
Table 1. Blautia response in gut microbiota changes due to diet in adult subjects.
Refs.InducerEffect on BlautiaStatusFB RatioMethod UsedTreatment PeriodCountryBlautia Related Findings
Jie et al. 2021 [54]dietary and exercise(−)Goodndmetagenomic shotgun sequencing24 weeksChinaB. wexlerae was the strongest predictors for weight loss when present in high abundance at baseline.
Cuevas-Sierra et al. [55]Medium protein & low-fat diets(−)Goodnd16S rRNA, V3–V4 region sequencing16 weeksSpainBlautia was negatively correlated with BMI loss percentage in women on a low-fat diet.
Gómez-Pérez et al. 2022 [42]Mediterranean diet and exercise(−)GoodReduced16S rRNA, V2–V9 region sequencing48 weeksSpainDecrease in Blautia may be associated with the development of non-alcoholic fatty liver disease.
Yuan et al. 2022 [58]improved ketogenic diet(+)BadReduced16S rRNA, V3–V4 region sequencing12 weeksChinaDecreased the abundance of Blautia and enhanced weight loss in obese individuals.
Wang et al. 2023 [59]hypocaloric balanced diet(+)BadReduced16S rRNA, V3–V4 region sequencing12 weeksChinaDiet led to significant weight loss and changes in the gut microbiota of obese individuals, including a decrease in the abundance of Blautia.
Medawar et al. 2021 [60]eating habits and Roux-en-Y gastric bypass(−)Goodnd16S rRNA, V3–V4 region sequencingNAGermanyBlautia abundance correlated with healthier eating behavior, but this was reduced with Roux-en-Y gastric bypass.
Wang et al. 2023 [56]improved ketogenic diet and exercise(−)Goodndmetagenomic sequencing12 weeksChinaB. obeum was positively associated with VFA, while a negative association was observed with B. producta, B. hansenii, B. wexlerae, and Blautia sp. CAG257.
Pataky et al. 2016 [57]hypocaloric hyperproteic diet (−)Goodndshotgun metagenomics3 weeksSwitzerlandBlautia was negatively associated with changes in the body fat mass.
nd: not determined, NA: not applicable, (−): negative association, and (+): positive association.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chanda, W.; Jiang, H.; Liu, S.-J. The Ambiguous Correlation of Blautia with Obesity: A Systematic Review. Microorganisms 2024, 12, 1768. https://doi.org/10.3390/microorganisms12091768

AMA Style

Chanda W, Jiang H, Liu S-J. The Ambiguous Correlation of Blautia with Obesity: A Systematic Review. Microorganisms. 2024; 12(9):1768. https://doi.org/10.3390/microorganisms12091768

Chicago/Turabian Style

Chanda, Warren, He Jiang, and Shuang-Jiang Liu. 2024. "The Ambiguous Correlation of Blautia with Obesity: A Systematic Review" Microorganisms 12, no. 9: 1768. https://doi.org/10.3390/microorganisms12091768

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop